Back to Search
Start Over
A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer
- Source :
- Asia-Pacific Journal of Clinical Oncology. 6:292-297
- Publication Year :
- 2010
- Publisher :
- Wiley, 2010.
-
Abstract
- Aim: KW-2170 is a novel pyrazoloacridone derivative that intercalates nucleic acids. It has promising in vitro properties against prostate and other cancers and is active in vivo against doxorubicin-resistant cell lines. We wished to investigate its activity and toxicity profile in this Phase II trial in androgen independent prostate cancer. Methods: Overall 44 men were recruited to this multicenter, open label, non-randomized study, with 35 evaluable for prostatic specific antigen (PSA) response. Results: Five patients had a PSA fall greater than 50% (overall RR 14.3%, 95% CI 4.8–30.3%). Overall median survival was 16 months. In the evaluable group (n = 35), median survival was 18.9 months. The drug was very well tolerated, with the most common toxicities being hematological (anemia, leucopenia, thrombocytopenia), alopecia, fatigue, and nausea. However, most of these were National Cancer Institute Grade 1 or 2; Grade 3 neutropenia occurred in only 11% of patients, and there was no Grade 4 neutropenia. Quality of life as measured by the FACT–P scale was not compromised. Conclusion: KW-2170 is a very well tolerated chemotherapy agent. It has a relatively low PSA response rate, and did not meet the pre-specifed criteria for further studies.
- Subjects :
- Gynecology
medicine.medical_specialty
Chemotherapy
Anthracycline
business.industry
Anemia
Nausea
medicine.medical_treatment
Cancer
General Medicine
Neutropenia
medicine.disease
Gastroenterology
medicine.anatomical_structure
Oncology
Prostate
Internal medicine
medicine
medicine.symptom
business
Survival rate
Subjects
Details
- ISSN :
- 17437555
- Volume :
- 6
- Database :
- OpenAIRE
- Journal :
- Asia-Pacific Journal of Clinical Oncology
- Accession number :
- edsair.doi...........39c52ce8d9759a492cab7e50a82cffe6